297 related articles for article (PubMed ID: 22991059)
21. Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma.
Spencer SJ; Guzauskas GF; FeLizzi F; Launonen A; Dawson K; Veenstra DL; Masaquel A
J Manag Care Spec Pharm; 2021 May; 27(5):615-624. PubMed ID: 33586513
[No Abstract] [Full Text] [Related]
22. Mechanism-based approach to the economic evaluation of pharmaceuticals: pharmacokinetic/pharmacodynamic/pharmacoeconomic analysis of rituximab for follicular lymphoma.
Pink J; Lane S; Hughes DA
Pharmacoeconomics; 2012 May; 30(5):413-29. PubMed ID: 22428718
[TBL] [Abstract][Full Text] [Related]
23. [Economic evaluation of rituximab added to fludarabine plus cyclophosphamide versus fludarabine plus cyclophosphamide for the treatment of chronic lymphocytic leukemia].
Casado LF; García Marco JA; Gilsanz F; González M; Ríos E; de la Serna J; Urbano A; Vicente V; Rubio-Terrés C; Castro AJ
Gac Sanit; 2011; 25(4):274-81. PubMed ID: 21664727
[TBL] [Abstract][Full Text] [Related]
24. The cost-effectiveness of immediate treatment or watch and wait with deferred chemotherapy for advanced asymptomatic follicular lymphoma.
Prettyjohns M; Hoskin P; McNamara C; Linch D;
Br J Haematol; 2018 Jan; 180(1):52-59. PubMed ID: 29076139
[TBL] [Abstract][Full Text] [Related]
25. Cost effectiveness of prostacyclins in pulmonary arterial hypertension.
Roman A; Barberà JA; Escribano P; Sala ML; Febrer L; Oyagüez I; Sabater E; Casado MA
Appl Health Econ Health Policy; 2012 May; 10(3):175-88. PubMed ID: 22452448
[TBL] [Abstract][Full Text] [Related]
26. Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis.
Vidal L; Gafter-Gvili A; Salles G; Bousseta S; Oberman B; Rubin C; van Oers MH; Fortpied C; Ghielmini M; Pettengell R; Witzens-Harig M; Dreger P; Vitolo U; Gomes da Silva M; Evangelista A; Li H; Freedman L; Habermann TM; Shpilberg O
Eur J Cancer; 2017 May; 76():216-225. PubMed ID: 28336303
[TBL] [Abstract][Full Text] [Related]
27. Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma : An Evidence Review Group Evaluation of the NICE Single Technology Appraisal.
Thielen FW; Büyükkaramikli NC; Riemsma R; Fayter D; Armstrong N; Wei CY; Huertas Carrera V; Misso K; Worthy G; Kleijnen J; Corro Ramos I
Pharmacoeconomics; 2019 Aug; 37(8):975-984. PubMed ID: 30547368
[TBL] [Abstract][Full Text] [Related]
28. Development of a population-based cost-effectiveness model of chronic graft-versus-host disease in Spain.
Crespo C; Pérez-Simón JA; Rodríguez JM; Sierra J; Brosa M
Clin Ther; 2012 Aug; 34(8):1774-87. PubMed ID: 22835778
[TBL] [Abstract][Full Text] [Related]
29. Modelling the cost effectiveness of rituximab in chronic lymphocytic leukaemia in first-line therapy and following relapse.
Adena M; Houltram J; Mulligan SP; Todd C; Malanos G
Pharmacoeconomics; 2014 Feb; 32(2):193-207. PubMed ID: 24442832
[TBL] [Abstract][Full Text] [Related]
30. Rituximab maintenance versus retreatment in follicular lymphoma.
Palla AR; Hamadani M
Hematol Oncol; 2013 Dec; 31(4):171-8. PubMed ID: 23044794
[TBL] [Abstract][Full Text] [Related]
31. Maintenance rituximab should be considered for patients with follicular lymphoma.
Barr PM
Clin Adv Hematol Oncol; 2014 Aug; 12(8):541-3. PubMed ID: 25356579
[No Abstract] [Full Text] [Related]
32. Is there a role for "watch and wait" in follicular lymphoma in the rituximab era?
Kahl B
Hematology Am Soc Hematol Educ Program; 2012; 2012():433-8. PubMed ID: 23233615
[TBL] [Abstract][Full Text] [Related]
33. Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma.
Dundar Y; Bagust A; Hounsome J; McLeod C; Boland A; Davis H; Walley T; Dickson R
Health Technol Assess; 2009 Jun; 13 Suppl 1():23-8. PubMed ID: 19567210
[TBL] [Abstract][Full Text] [Related]
34. Rituximab maintenance therapy for follicular lymphoma: no better than watchful waiting.
Prescrire Int; 2012 Mar; 21(125):62. PubMed ID: 22428182
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US.
Guzauskas GF; Masaquel A; Reyes C; Bernaards C; Krivasi T; Veenstra DL
J Med Econ; 2018 Oct; 21(10):960-967. PubMed ID: 29898619
[TBL] [Abstract][Full Text] [Related]
36. Economic burden of follicular non-Hodgkin's lymphoma.
Foster T; Miller JD; Boye ME; Russell MW
Pharmacoeconomics; 2009; 27(8):657-79. PubMed ID: 19712009
[TBL] [Abstract][Full Text] [Related]
37. The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States.
Nastoupil LJ; Sinha R; Byrtek M; Zhou X; Taylor MD; Friedberg JW; Link BK; Cerhan JR; Dawson K; Flowers CR
Cancer; 2014 Jun; 120(12):1830-7. PubMed ID: 24668580
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
Wu B; Chen H; Shen J; Ye M
Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
[TBL] [Abstract][Full Text] [Related]
39. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
40. Rituximab maintenance therapy until progression after rituximab and chemotherapy induction in patients with follicular lymphoma.
Yared J; Kimball A; Baer MR; Bahrain H; Auerbach M
Clin Lymphoma Myeloma Leuk; 2013 Jun; 13(3):253-7. PubMed ID: 23352637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
